Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Open access
Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P.A., Baurain, J -F, Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., Tse, A., Douillard, J -Y, Tabernero, J., Haanen, J., Brody, J. · 2018 · Annals of Oncology

Abstract

A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were representatives of ESMO. The focus of the meeting was exclusively on the intratumoral injection/delivery of immunostimulatory agents with the aim of harmonizing the standard terms and methodologies used in the reporting of human intratumoral immunotherapy (HIT-IT) clinical trials to ensure quality assurance and avoid a blurring of the data reported from different studies. The goal was to provide a reference document, endorsed by the panel members that could provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent review boards, patient advocates and the regulatory authorities and promote an increase in the number and quality of HIT-IT clinical trials in the future. Particular emphasis was placed not only on the development of precise definitions to facilitate a better understanding between investigators but also on the importance of systematic serial biopsies as a driver for translational research and the need for the recording and reporting of data, to facilitate a better understanding of the key processes involved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy423

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 215

Metadata

Authors
Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P. A., Baurain, J. F., Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., Tse, A., Douillard, J. Y., Tabernero, J., Haanen, J., & Brody, J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-11
Volume
29
Issue
11
Pages
2163-2174
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2897639828
Cited by
215
References
1
FWCI
7.50
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). https://app.cochat.ai/papers/10.1093/annonc/mdy423
The paper
Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P. A., Baurain, J. F., Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., . . . Brody, J. (2018). Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Annals of Oncology. https://doi.org/10.1093/annonc/mdy423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.